

CADTH Reference List

# DaTscan for Diagnosing Movement Disorders

August 2021

**Authors:** Thyna Vu, Jennifer Horton

**Cite As:** *DaTscan for Diagnosing Movement Disorders*. (CADTH reference list: summary of abstracts). Ottawa: CADTH; 2021 Aug.

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Key Messages

- No evidence was identified regarding the cost-effectiveness of DaTscan for the diagnosis of movement disorders.
- Two evidence-based guidelines were identified regarding the use of DaTscan for the diagnosis of movement disorders.

## Research Questions

1. What is the cost-effectiveness of DaTscan for the diagnosis of movement disorders?
2. What are the evidence-based guidelines regarding the use of DaTscan for the diagnosis of movement disorders?

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concept was DaTscan. No filters were applied to limit the retrieval by study type. When possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2016, and August 10, 2021. Internet links were provided, if available.

### Selection Criteria and Summary Methods

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. The Overall Summary of Findings was based on information available in the abstracts of selected publications. Open-access full-text versions of evidence-based guidelines were reviewed when abstracts were not available, and relevant recommendations were summarized.

## Results

Two evidence-based guidelines regarding the use of DaTscan for the diagnosis of movement disorders were identified.<sup>1,2</sup> No relevant health technology assessments, systematic reviews, or economic evaluations were identified.

**Table 1: Selection Criteria**

Criteria	Description
<b>Population</b>	Patients with a suspected movement disorder (i.e., disorders associated with dopaminergic neurodegeneration, such as Parkinson disease, multiple system atrophy, or progressive supranuclear palsy)
<b>Intervention</b>	DaTscan (dopamine transporter scan)
<b>Comparator</b>	Q1: Standard clinical assessment (e.g., MRI or CT and clinical assessment) Q2: Not applicable
<b>Outcomes</b>	Q1: Cost-effectiveness (e.g., quality-adjusted life-years/cost, incremental cost-effectiveness ratios) Q2: Recommendations regarding the use of DaTscan for diagnosis of movement disorders
<b>Study designs</b>	Health technology assessments, systematic reviews, economic evaluations, evidence-based guidelines

DaTscan = dopamine transporter scan.

Additional references of potential interest that did not meet the inclusion criteria are provided in Appendix 1.

## Overall Summary of Findings

Two evidence-based guidelines regarding the use of DaTscan for the diagnosis of movement disorders were identified.<sup>1,2</sup> The Canadian guideline for Parkinson disease recommends that 123I-ioflupane (DaTscan) be used with single-photon emission computed tomography (SPECT) scanning (<sup>123</sup>I-FP-CIT SPECT) to aid clinical diagnosis in patients when there is uncertainty between Parkinson disease and nondegenerative parkinsonism or tremor disorders.<sup>1</sup> The National Institute for Clinical Excellence (NICE) guideline recommends that <sup>123</sup>I-FP-CIT SPECT be used for people with tremor if essential tremor cannot be clinically differentiated from parkinsonism.<sup>2</sup> NICE also recommends that <sup>123</sup>I-FP-CIT SPECT should be available for specialists with expertise in its use and interpretation.<sup>2</sup>

No relevant literature was found regarding the cost-effectiveness of DaTscan for the diagnosis of movement disorders; therefore, no summary can be provided.

## References

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-Analyses

No literature identified.

### Economic Evaluations

No literature identified.

### Guidelines and Recommendations

1. Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. *CMAJ*. 2019 09;191(36): E989-E1004. <https://www.cmaj.ca/content/191/36/E989> Accessed 2021 Aug 12.  
See: Table 2: Summary of recommendations for diagnosis and progression – Recommendation number C17.
2. National Institute for Health and Care Excellence. Parkinson's disease in adults. (*NICE guideline NG71*) 2017; <https://www.nice.org.uk/guidance/ng71> Accessed 2021 Aug 12.  
See: 1.2 Diagnosing Parkinson's disease – Single photon emission computed tomography (p.7)

## Appendix 1: References of Potential Interest

### Economic Evaluations

#### *Budget Impact: Impact of Reimbursement Cuts*

3. Covington MF, McMillan NA, Kuo PH. Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine transporter Imaging. *J Am Coll Radiol*. 2016 09;13(9):1039-1043. [PubMed](#)

### Clinical Practice Guidelines and Recommendations

#### *Unclear Methodology*

4. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. *Eur J Nucl Med Mol Imaging*. 2020 07;47(8):1885-1912. [PubMed](#)
5. ACR Committee on Appropriateness Criteria. Movement Disorders and Neurodegenerative Diseases. Reston (VA): American College of Radiology; 2019. <https://acsearch.acr.org/docs/3111293/Narrative/> Accessed 2021 Aug 12.  
See: Variant 3: Parkinsonian Syndromes. Initial Imaging – Ioflupane SPECT/CT Brain (p. 2)
6. Grabher BJ. Datscan Imaging. *J Nucl Med Technol*. 2019 03;47(1):27-28. [PubMed](#)
7. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. *Clin Nucl Med*. 2017 11;42(11):847-852. [PubMed](#)

### Review Articles

8. Akdemir UO, Bora Tokcaer A, Atay LO. Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders. *Turk J Med Sci*. 2021 04;51(2):400-410. [PubMed](#)
9. Thobois S, Prange S, Scheiber C, Broussolle E. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. *Parkinsonism Relat Disord*. 2019 02;59:93-100. [PubMed](#)
10. LaFaver K, Espay AJ. Diagnosis and Treatment of Functional (Psychogenic) Parkinsonism. *Semin Neurol*. 2017 04;37(2):228-232. [PubMed](#)
11. Rodriguez-Porcel F, Jamali S, Duker AP, Espay AJ. Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user's guide. *Expert Rev Neurother*. 2016;16(1):23-29. [PubMed](#)

### Additional References

12. Galbraith K. Is DaTSCAN cost-effective as a diagnostic tool in uncertain Parkinson's? *Critically Appraised Topics*. London (UK): UK Parkinson's Excellence Network; 2016. <https://www.parkinsons.org.uk/sites/default/files/2017-07/RD2734%20DaTCAT%20cost%20effectiveness.pdf> Accessed 2021 Aug 12.  
See: Clinical Bottom Line (p. 1)
13. Gomez-Rio M, Caballero MM, Gorris Saez JM, Minguéz-Castellanos A. Diagnosis of Neurodegenerative Diseases: The Clinical Approach. *Curr Alzheimer Res*. 2016;13(5):469-474. [PubMed](#)
14. Parkinson's UK. Clinical Summary: Use of DaTSCAN. *Diagnosis of Parkinson's disease: use of presynaptic dopaminergic imaging*. N.d. <https://www.parkinsons.org.uk/professionals/clinical-summary-use-datscan> Accessed 2021 Aug 12.